Literature DB >> 9193864

Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy.

D Honeybourne1.   

Abstract

There has been an increasing amount of information published recently about the ability of different antimicrobial agents to penetrate specific areas of the lung. Initially, whole lung concentrations were reported, but this methodology has been refined so that levels are now measured in potential sites of infection, such as the bronchial mucosa, epithelial lining fluid, and alveolar macrophages, as well as in sputum. Distinct differences in the ability to concentrate in these sites have been shown among beta-lactams, quinolones, and macrolides. Considerable intracellular concentration of quinolones and macrolides, but not beta-lactams, occurs. This intracellular accumulation has been used for the treatment of atypical mycobacteria. The potential effects of high antibiotic levels on cellular function have also been investigated. The clinical relevance of these findings for the choice of antimicrobial agent, dosage, formulation (eg, liposomal), and route of administration (eg, nebulized) are increasingly being explored.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9193864     DOI: 10.1097/00063198-199703000-00014

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  11 in total

1.  BTS Guidelines for the Management of Community Acquired Pneumonia in Adults.

Authors: 
Journal:  Thorax       Date:  2001-12       Impact factor: 9.139

2.  Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis.

Authors:  M A Zeitlinger; P Dehghanyar; B X Mayer; B S Schenk; U Neckel; G Heinz; A Georgopoulos; M Müller; C Joukhadar
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

Review 3.  Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.

Authors:  Keith A Rodvold; Jomy M George; Liz Yoo
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

4.  Kinetics and intrapulmonary disposition of tilmicosin after single and repeated oral bolus administrations to rabbits.

Authors:  G Gallina; L Lucatello; I Drigo; M Cocchi; S Scandurra; F Agnoletti; C Montesissa
Journal:  Vet Res Commun       Date:  2010-06       Impact factor: 2.459

5.  Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen.

Authors:  Blair Capitano; Brian A Potoski; Shahid Husain; Shimin Zhang; David L Paterson; Sean M Studer; Kenneth R McCurry; Raman Venkataramanan
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

6.  High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions.

Authors:  Brendan Prideaux; Véronique Dartois; Dieter Staab; Danielle M Weiner; Anne Goh; Laura E Via; Clifton E Barry; Markus Stoeckli
Journal:  Anal Chem       Date:  2011-02-18       Impact factor: 6.986

7.  Penetration of Ciprofloxacin and Amikacin into the Alveolar Epithelial Lining Fluid of Rats with Pulmonary Fibrosis.

Authors:  Wentao Ni; Deqing Yang; Hekun Mei; Jin Zhao; Beibei Liang; Nan Bai; Dong Chai; Junchang Cui; Rui Wang; Youning Liu
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

8.  Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647).

Authors:  C Muller-Serieys; P Soler; C Cantalloube; F Lemaitre; H P Gia; F Brunner; A Andremont
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 9.  Nebulized anticoagulants for acute lung injury - a systematic review of preclinical and clinical investigations.

Authors:  Pieter R Tuinman; Barry Dixon; Marcel Levi; Nicole P Juffermans; Marcus J Schultz
Journal:  Crit Care       Date:  2012-12-12       Impact factor: 9.097

10.  Feasibility and Safety of Local Treatment with Recombinant Human Tissue Factor Pathway Inhibitor in a Rat Model of Streptococcus pneumoniae Pneumonia.

Authors:  Florry E van den Boogaard; Jorrit J Hofstra; Cornelis van 't Veer; Marcel M Levi; Joris J T H Roelofs; Tom van der Poll; Marcus J Schultz
Journal:  PLoS One       Date:  2015-05-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.